thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
=== 1950s === In 1953, the company became a public company via an initial public offering on the New York Stock Exchange. In 1954, the company acquired Davison Chemical Company and Dewey & Almy Chemical Company, entering the specialty chemicals and specialty materials industries and establishing the basis for the current product lines. In 1955, the company elected a chairman of the company who was not a member of the Grace family, which was a first in the 101-year history of company. The company appointed Charles E. Wilson, who was the former CEO of General Electric. His predecessor for his position was William Grace Holloway.
Apitegromab, sold under the brand name Isembyld, is a fully human IgG4 lambda monoclonal antibody used for the treatment of spinal muscular atrophy. It is a recombinant monoclonal antibody targeting proforms of myostatin. The most common side effects include upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat). Apitegromab was approved for to treat Spinal Muscular Atrophy in the United States in September 2026.
3-D Viewer of a male American mastodon skeleton, with bones labelled, at the University of Michigan Mammutidae digital fossil repository Interactive views of various primate skeletons at eSkeletons.org (associated with the University of Texas at Austin)
== References == Cooper, Paul W. (1996). Explosives Engineering. New York: Wiley-VCH. ISBN 978-0-471-18636-6. OCLC 34409473. Retrieved 9 June 2014. Urbanski, Tadeusz (1967). Chemistry and Technology of Explosives. Vol. III. Warszawa: Polish Scientific Publishers.
== External links == National Isotope Development Center U.S. Government resources for isotopes - production, distribution, and information Isotope Development & Production for Research and Applications (IDPRA) U.S. Department of Energy program sponsoring isotope production and production research and development
Sources: en.wikipedia.org
As an analytical technique, RIS is useful based on some of its working operations – they include extremely low detection limit so that mass of samples could be identified up to the order of 10−15, the extremely high sensitivity and elemental selectivity useful in micro- and trace analysis when coupled with mass spectrometers, and ability of the pulsed laser ion source to produce pure isobaric ion beams. A major advantage of using resonance ionization is that it is a highly selective ionization mode; it is able to target a single type of atom among a background of many types of atoms, even when said background atoms are much more abundant than the target atoms. In addition, resonance ionization incorporates the high selectivity that is desired in spectroscopy methods with ultrasensitivity, thus making resonance ionization useful when analyzing complex samples with several atomic components. Resonance ionization spectroscopy (RIS) thus has a wide range of research and industrial applications. These include characterizing the diffusion and chemical reaction of free atoms in a gas medium, solid state surface analysis using direct sampling, studying the degree of concentration variations in a dilute vapor, detecting the allowable limits of number of particles needed in a semiconductor device, and estimating the flux of solar neutrinos on Earth.
, the spreading slows down thus useful to set a prediction on the short-term trends. Also, it can be used to directly calculate the threshold population of vaccination/immunization for the herd immunity stage by setting
== Reception == Ben Rogers reviewed the Fat Duck for The Independent in 1996, before it had gained any Michelin stars. He discovered that Blumenthal was cooking foie gras in sherry to give it a nutty flavour, but Rogers was not sure if this was warranted. He praised a jambonneau of duck, but found the monkfish rubbery. He described the menu as "awkwardly written, badly punctuated, and at points quite impenetrable". After the Fat Duck received its first Michelin star, David Fingleton visited it for The Spectator in 1999, and found the experience "beyond reproach; unsullied pleasure from start to finish". In 2001, Terry Durack reviewed the Fat Duck for The Independent. He was initially hesitant, expecting tricks straight away, but was surprised to find a bowl of normal green olives on the table as he arrived. He did not enjoy a mustard ice cream in a red cabbage gazpacho soup, but described the restaurant as "great" and gave it a score of 17 out of 20. In 2004, following the third Michelin star, Jan Moir of The Daily Telegraph gave it a negative review, saying that "while many of the flavours are politely interesting, the relentless pappy textures of mousses and foams and creams and poached meats really begins to grate". She also found it overpriced, calling it the "Fat Profit". Matthew Fort reviewed the Fat Duck for The Guardian in 2005, and wrote that "there is no doubt that the Fat Duck is a great restaurant and Heston Blumenthal the most original and remarkable chef this country has ever produced". In The Times, A. A.
== Historiography == Berger, Henry W. ed. A William Appleman Williams Reader (1992). Ferrell, Robert H. Harry S. Truman and the Cold War Revisionists. (2006). 142 pp. excerpt and text search. Fitzpatrick, Sheila. "Russia's Twentieth Century in History and Historiography," The Australian Journal of Politics and History, Vol. 46, 2000. Gardner, Lloyd C. (ed.) Redefining the Past: Essays in Diplomatic History in Honor of William Appleman Williams (1986). Garthoff, Raymond L. "Foreign Intelligence and the Historiography of the Cold War." Journal of Cold War Studies 2004 6(2): 21–56. ISSN 1520-3972 Fulltext: Project MUSE. Isaac, Joel; Bell, Duncan, eds. Uncertain Empire: American History and the Idea of the Cold War (2012) online review by Victoria Hallinan. Kaplan, Lawrence S. American Historians and the Atlantic Alliance, (1991) online edition.. Kort, Michael. The Columbia Guide to the Cold War (1998). Matlock, Jack E. "The End of the Cold War" Harvard International Review, Vol. 23 (2001). Melanson, Richard A. "Revisionism Subdued? Robert James Maddox and the Origins of the Cold War" Political Science Reviewer, Vol. 7 (1977). Melanson, Richard A. Writing History and making Policy: The Cold War, Vietnam, and Revisionism (1983). Olesen, Thorsten B.Ed. The Cold War and the Nordic Countries: Historiography at a Crossroads. Odense: U Southern Denmark Press, 2004. Pp. 194. online review. Stephanson, Anders. American Imperatives: The Cold War and Other Matters, Verso Books, 2025 Suri, Jeremi.
=== Phase 3 === Altropane (123-I Altropane; [123I]-E-IACFT; NAV-5001; O-587) – dopamine reuptake inhibitor (DRI) and single-photon emission-computed tomography (SPECT) enhancer [3] Apomorphine (Aporon) – non-selective dopamine receptor agonist and other actions [4] Apomorphine sublingual film (APL-130277; Kynmobi) – non-selective dopamine receptor agonist and other actions [5] Bemdaneprocel (BRT-DA01; DA-01; MSK-DA01; pluripotent stem cell derived dopaminergic neurons) – dopaminergic cell replacement [6] Buntanetap ((+)-(3aR)-phenserine; (+)-phenserine; ANVS-401; ANVS-405; ANVS402; posiphen) – various actions [7] 18F-LBT-999 ([18F]-LBT-999; LBT-999) – dopamine reuptake inhibitor (DRI) and positron-emission tomography (PET) enhancer – diagnosis [8] Nabilone controlled release (Nabilone FDT) – cannabinoid CB1 and CB2 receptor agonist [9] Pramipexole/rasagiline (P2B-001; rasagiline/pramipexole) – combination of pramipexole (dopamine D2-like receptor agonist) and rasagiline (MAO-B inhibitor) [10] Remlifanserin (ACP-204) – serotonin 5-HT2A receptor antagonist – Parkinson's disease psychosis [11] Solengepras (CVN-424) – G protein-coupled receptor 6 (GPR6) inhibitor [12] Tavapadon (CVL-751; PF-6649751; PF-06649751) – dopamine D1 and D5 receptor agonist [13]
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.